Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
94.38
0.00 (-0.01%)
Oct 9, 2025, 11:51 AM EDT - Market open
Merus Revenue
Merus had revenue of $8.83M in the quarter ending June 30, 2025, with 20.40% growth. This brings the company's revenue in the last twelve months to $56.23M, up 59.77% year-over-year. In the year 2024, Merus had annual revenue of $36.13M, down -17.78%.
Revenue (ttm)
$56.23M
Revenue Growth
+59.77%
P/S Ratio
116.21
Revenue / Employee
$175,165
Employees
321
Market Cap
7.15B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36.13M | -7.81M | -17.78% |
Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MRUS News
- 8 days ago - MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 10 days ago - Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough - Benzinga
- 10 days ago - This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired. - Barrons
- 10 days ago - Months after cancer drug trial, Merus agrees to be bought at 41% premium - Market Watch
- 10 days ago - Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline - Invezz
- 10 days ago - Genmab to buy Dutch cancer drugmaker Merus for $8 billion - Reuters
- 10 days ago - Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - Business Wire
- 6 weeks ago - Merus to Present at the 2025 Wells Fargo Healthcare Conference - GlobeNewsWire